
    
      The study consisted of a:

        -  Up to 2 weeks screening period

        -  26-week treatment period

        -  26-week comparative safety extension period

        -  1-day follow-up period

        -  The maximum study duration would be 54 weeks per participant and a 1-day safety
           follow-up
    
  